In a patient with yeast isolated from cultures, already receiving co‑amoxiclav and who has failed cotrimoxazole twice, what fluconazole dosing and co‑amoxiclav regimen should be used until the second‑stage stone removal?

Fluconazole Dosing for Urologic Yeast Infection with Planned Stone Removal

For a patient with yeast isolated from cultures who is undergoing urologic stone removal, fluconazole 400 mg (6 mg/kg) daily should be initiated several days before the procedure and continued for several days after, with co-amoxiclav continued at standard dosing until definitive surgical intervention. 1

Antifungal Management

Pre-procedural Fluconazole Dosing

The IDSA 2016 guidelines provide explicit recommendations for patients undergoing urologic procedures with candiduria:

• Fluconazole 400 mg (6 mg/kg) daily starting several days before the urologic manipulation and continuing for several days after the procedure 1
• This represents a strong recommendation with low-quality evidence but is the only guideline-directed approach for this specific clinical scenario

Species-Specific Considerations

Once yeast speciation is available, adjust therapy accordingly:

• For fluconazole-susceptible organisms (most Candida albicans, C. parapsilosis, C. tropicalis): Continue fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks post-procedure if pyelonephritis is present 1
• For Candida glabrata: Many isolates show intermediate susceptibility; use the higher fluconazole dose (400 mg daily) or consider amphotericin B 0.3-0.6 mg/kg daily 1
• For Candida krusei: Intrinsically resistant to fluconazole; requires amphotericin B 0.3-0.6 mg/kg daily 1

Duration of Therapy

• Minimum 2 weeks for fluconazole-susceptible organisms with pyelonephritis 1
• Continue until elimination of urinary tract obstruction (stone removal) is achieved 1
• Shorter courses (several days) may suffice if limited to asymptomatic candiduria in the perioperative period 1

Antibacterial Management

Co-amoxiclav Continuation

Continue co-amoxiclav at standard dosing (typically 875/125 mg twice daily or 500/125 mg three times daily) until the stone removal procedure, as:

• The patient has already failed cotrimoxazole twice, indicating either bacterial resistance or inadequate tissue penetration
• Co-amoxiclav provides broader coverage for urinary pathogens including E. coli, Proteus, and Enterococcus species
• Urologic stone procedures carry high risk for bacterial superinfection

Important Caveat on Cotrimoxazole Failure

The double failure of cotrimoxazole suggests:

• Bacterial resistance (increasingly common with TMP-SMX)
• Possible biofilm formation on the stone surface
• Need for definitive source control (stone removal) rather than prolonged antibiotic suppression

Critical Management Points

Source Control Priority

Surgical stone removal is essential 1:

• Elimination of urinary tract obstruction is a strong recommendation 1
• Stones serve as nidus for persistent infection (both bacterial and fungal)
• Medical therapy alone is unlikely to achieve cure without stone removal

Catheter Management

If an indwelling bladder catheter is present:

• Remove or replace the catheter if feasible 1
• This is a strong recommendation as catheters are major predisposing factors for candiduria 1

High-Risk Patient Considerations

This patient requires antifungal treatment (not just observation) because they are undergoing urologic manipulation, placing them in the high-risk category for dissemination 1:

• Neutropenic patients
• Very low-birth-weight infants (<1500 g)
• Patients undergoing urologic procedures ← This patient

Drug Interactions

Monitor for potential fluconazole-amoxicillin interaction:

• Fluconazole is a moderate CYP3A4 inhibitor but does not significantly interact with beta-lactams 2
• Co-amoxiclav does not require dose adjustment when combined with fluconazole
• Both drugs can be administered without regard to meals 2

Common Pitfalls to Avoid

1. Do not withhold antifungal therapy pending speciation—start fluconazole empirically given the planned urologic procedure 1

2. Do not use fluconazole monotherapy if bacterial co-infection is suspected—continue antibacterial coverage until stone removal 1

3. Do not assume asymptomatic candiduria is benign in the setting of planned urologic manipulation—this patient requires treatment 1

4. Do not use inadequate fluconazole dosing—the perioperative dose is 400 mg daily, not the lower 200 mg dose used for simple cystitis 1

5. Avoid amphotericin B bladder irrigation as primary therapy—this is reserved for fluconazole-resistant species and is a weak recommendation 1